Abstract
ABSTRACTPurpose: Moxifloxacin (MXN) is widely prescribed for the treatment of bacterial keratitis. The conventional MXN solution has several limitations, including short precorneal residence time and poor intrastromal bioavailability, requiring frequent instillation of the drug to achieve the desired therapeutic effect. To circumvent this problem, the W/O (water-in-oil) microemulsion (ME) system was utilized for sustained release and improved precorneal retention.Methods: The pseudo-ternary phase diagrams were developed and various MEs were prepared using two non-ionic surfactants, Tween 80 and Span 20, with isopropyl myristate and acetate buffer. Physicochemical parameters, in vitro drug release and in vitro antibacterial activity were studied. The in vivo antimicrobial efficacy of optimized microemulsion (ME 10) was studied in an experiment on bacterial keratitis in rabbit eyes and compared with that of the marketed eye drops.Results: The optimized microemulsion (ME 10) displays as an average globule size of <40 nm. The developed MEs showed acceptable physico-chemical behaviour, good stability for 3 months and exhibited sustained drug release. Greater efficacy in experimental bacterial keratitis in rabbit eyes was also observed in comparison with marketed drug solution.Conclusions: The developed MEs are a viable alternative to conventional eye drops, because of its ability to enhance bioavailability through its longer precorneal residence time and its ability to sustain the release of the drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.